D.W. Erkelens

EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME

Ton J. Rabelink, D.W. Erkelens, R. J. Hené et al. · The Lancet · 1988 · 89 citations

Metabolic Syndrome, Lipid Disorder, Vascular Disease +11

Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin

D. Roger Illingworth, D.W. Erkelens, Ulrich Keller et al. · The Lancet · 1994 · 67 citations

Daily Doses, Cardiovascular Disease, Medicine +4

Cost effectiveness of cholesterol-lowering therapy in The Netherlands

Léon L. Martens, Frans Rutten, D.W. Erkelens et al. · The American Journal of Medicine · 1989 · 55 citations

Preventive Medicine, Cardiovascular Disease, Health Economics +6

Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: The case of simvastatin and cholestyramine in The Netherlands

Léon L. Martens, Frans Rutten, D.W. Erkelens et al. · The American Journal of Cardiology · 1990 · 52 citations

Lipid Disorder, Health Economics, Health Policy +8

Plasma lipids and apoproteins, body fat distribution and body fatness in early pubertal children.

Maria L. Zonderland, W. Erich, D.W. Erkelens et al. · PubMed · 1990 · 23 citations